Search results for " Randomized Controlled Trials"

showing 10 items of 36 documents

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malatti…

OncologyMaleCancer ResearchTime FactorsAngiogenesis InhibitorsKaplan-Meier Estimatelaw.invention0302 clinical medicineAutologous stem-cell transplantationMaintenance therapyRandomized controlled triallawRisk FactorsClinical endpointMedicine10. No inequalityLenalidomideAdjuvantMultiple myelomaRandomized Controlled Trials as TopicHematopoietic Stem Cell TransplantationMESH: Angiogenesis Inhibitors/administration & dosageORIGINAL REPORTSMiddle Aged3. Good healthThalidomideAdult; Aged; Angiogenesis Inhibitors; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide; Time Factors; Transplantation Autologous; Treatment Outcome; Young Adult; Stem Cell TransplantationTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisDisease ProgressionMESH: Multiple Myeloma/therapyFemaleMultiple MyelomaAutologousmedicine.drugAdultmedicine.medical_specialtyMESH: Thalidomide/analogs & derivatives[SDV.CAN]Life Sciences [q-bio]/CancerTransplantation AutologousDisease-Free SurvivalDrug Administration ScheduleMaintenance Chemotherapy03 medical and health sciencesYoung AdultInternal medicineChemotherapyHumansLenalidomideAgedTransplantationbusiness.industrymedicine.diseaseThalidomideTransplantationbusiness030215 immunologyStem Cell Transplantation
researchProduct

Sorafenib: from literature to clinical practice

2013

Sorafenib is considered the standard systemic therapy for hepatocellular carcinoma (HCC), in patients with well-preserved liver function (Child-Pugh A class) and advanced-stage HCC (BCLC-C) or in patients with HCC progressing after locoregional therapies, with a high grade of recommendation. The approval of sorafenib for this indication was grounded on the efficacy and the safety results reported by two international randomized, controlled trials, the SHARP and the Asia-Pacific studies. In addition, the efficacy and the safety of sorafenib in clinical practice are addressed by several field-practice experiences, including the multinational GIDEON study and the SOFIA study. Finally, further …

OncologyTime Factorsadverse eventPharmacologySystemic therapylaw.inventionTranslational Research Biomedicalobservational studieAntineoplastic AgentRandomized controlled trialRisk FactorslawMolecular Targeted TherapyHCCTranslational Medical Researchadverse events; clinical practice; observational studies; randomized clinical trials; sorafenib; Animals; Antineoplastic Agents; Carcinoma Hepatocellular; Evidence-Based Medicine; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Molecular Targeted Therapy; Translational Medical ResearchRandomized Controlled Trials as TopicEvidence-Based MedicineLiver NeoplasmsHematologyclinical practiceTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaHumanmedicine.drugNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorProtein Kinase InhibitorAntineoplastic AgentsInternal medicinemedicineAnimalsHumansAdverse effectProtein Kinase InhibitorsneoplasmsNeoplasm StagingAnimalbusiness.industryPhenylurea CompoundsRisk FactorEvidence-based medicinerandomized clinical trialmedicine.diseasedigestive system diseasessorafenibObservational studyLiver functionbusiness
researchProduct

Carbohydrate quality changes and concurrent changes in cardiovascular risk factors: a longitudinal analysis in the PREDIMED-Plus randomized trial.

2020

[Background]: Overall quality of dietary carbohydrate intake rather than total carbohydrate intake may determine the risk of cardiovascular disease (CVD).

PREDIMED-Plus carbohydrate carbohydrate quality index cardiovascular disease fiber glycemic index obesity randomized controlled trialsMaleobesity030309 nutrition & dieteticsMedicine (miscellaneous)030204 cardiovascular system & hematologyOverweightchemistry.chemical_compound0302 clinical medicinecardiovascular diseaseRisk FactorsSurveys and QuestionnairesGlycemic indexLongitudinal StudiesProspective Studies2. Zero hunger0303 health sciencesNutrition and DieteticsMiddle AgedCardiovascular disease3. Good healthGlycemic indexCardiovascular Diseasesrandomized controlled trialsRandomized controlled trialsFemalemedicine.symptomfibermedicine.medical_specialtyWaistCarbohydrates03 medical and health sciencesInternal medicinemedicineDietary CarbohydratesHumansFiberObesityAgedCarbohydrate quality indexTriglyceridebusiness.industryPREDIMED-PlusOverweightmedicine.diseaseObesityDietBlood pressurechemistrycarbohydratecarbohydrate quality indexglycemic indexGlycated hemoglobinMetabolic syndromebusinessEnergy Intake
researchProduct

Erythropoietin and subarachnoid hemorrhage.

2010

Pathologymedicine.medical_specialtySubarachnoid hemorrhageErytTime Factorserythropoietin subarachnoid hemorragelaw.inventionAnimals; Brain Ischemia; Clinical Trials; Phase II as Topic; Disease Models; Animal; Eryt; Humans; Neuroprotective Agents; Randomized Controlled Trials as Topic; Recombinant Proteins; Subarachnoid Hemorrhage; Time Factors; hropoietinBrain IschemiaBrain ischemialawmedicineAnimalsHumansClinical TrialsRandomized Controlled Trials as TopicSettore MED/27 - Neurochirurgiabusiness.industryAnimalPhase II as TopicGeneral MedicinehropoietinSubarachnoid Hemorrhagemedicine.diseaseRecombinant ProteinsNeuroprotective AgentsErythropoietinDisease ModelsRecombinant DNAbusinessmedicine.drug
researchProduct

Protective ventilation with high versus low positive end-expiratory pressure during one-lung ventilation for thoracic surgery (PROTHOR): study protoc…

2018

Postoperative pulmonary complications (PPC) may result in longer duration of in-hospital stay and even mortality. Both thoracic surgery and intraoperative mechanical ventilation settings add considerably to the risk of PPC. It is unclear if one-lung ventilation (OLV) for thoracic surgery with a strategy of intraoperative high positive end-expiratory pressure (PEEP) and recruitment maneuvers (RM) reduces PPC, compared to low PEEP without RM.PROTHOR is an international, multicenter, randomized, controlled, assessor-blinded, two-arm trial initiated by investigators of the PROtective VEntilation NETwork. In total, 2378 patients will be randomly assigned to one of two different intraoperative me…

Positive-Pressure RespirationMechanical ventilation; one-lung ventilation; positive end-expiratory pressure; postoperative pulmonary complication; recruitment maneuver; thoracic surgery; Humans; Intraoperative Complications; One-Lung Ventilation; Positive-Pressure Respiration; Research Design; Sample Size; Thoracic Surgical Procedures; Randomized Controlled Trials as TopicResearch DesignSample SizeHumansCorrectionThoracic Surgical ProceduresIntraoperative ComplicationsOne-Lung VentilationRandomized Controlled Trials as TopicTrials
researchProduct

Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view.

2014

Randomized Controlled Trials (RCTs) are the "gold standard" for evaluating treatment outcomes providing information on treatments "efficacy". They are designed to test a therapeutic hypothesis under optimal setting in the absence of confounding factors. For this reason they have high internal validity. The strict and controlled conditions in which they are conducted, leads to low generalizability because they are performed in conditions very different from real life usual care. Conversely, real life studies inform on the "effectiveness" of a treatment, that is, the measure of the extent to which an intervention does what is intended to do in routine circumstances. At variance to RCTs, real …

Pulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyAsthma; COPD; Randomized controlled trials; Real life studies; Asthma; Confounding Factors (Epidemiology); Humans; Pulmonary Disease Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)Alternative medicineSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionPulmonary DiseasePulmonary Disease Chronic ObstructiveRandomized controlled triallawIntervention (counseling)medicineCOPDHumansPharmacology (medical)Generalizability theoryMedical physicsInternal validityReal life studiesRandomized Controlled Trials as Topicbusiness.industryBiochemistry (medical)Gold standardConfounding Factors EpidemiologicVariance (accounting)Confounding Factors (Epidemiology)AsthmaReal life studieRandomized controlled trials; Real life studies; Asthma; COPDRandomized controlled trialResearch DesignRandomized controlled trialsPhysical therapybusinessStrengths and weaknesses
researchProduct

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics

2019

Background: Healthcare decisions made on the basis of insufficient evidence may potentially have ineffective or even harmful consequences. The proportion of older ages (over 65 years) in randomized controlled trials (RCTs) for severe asthma is not enough to establish whether anti-IL-5/IL-5R therapies are equally effective in the elderly as in younger subjects. Methods: In order to assess the relationship between age and the efficacy of anti-IL-5 monoclonal antibodies (mABs) with respect to the risk of exacerbations and changes in FEV1, a meta-regression analysis via random-effect method was carried out by plotting the effect estimates (outcome variables) resulting from the pairwise meta-ana…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergymABs monoclonal antibodiesSevere asthmamedicine.medical_specialtyExacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioImmunologyPopulationEosinophilArticlelaw.invention03 medical and health scienceschemistry.chemical_compoundAge0302 clinical medicineReslizumabRandomized controlled triallawInternal medicineImmunology and AllergyMedicine030223 otorhinolaryngologyeducationAsthmaEos eosinophilseducation.field_of_studybusiness.industryyrs yearsAnti-IL5medicine.diseaseBenralizumabEosinophilsRCTs Randomized Controlled TrialsClinical trial030228 respiratory systemchemistryTherapybusinesslcsh:RC581-607Mepolizumabmedicine.drug
researchProduct

Ten important articles on noninvasive ventilation in critically ill patients and insights for the future: A report of expert opinions

2017

Background Noninvasive ventilation is used worldwide in many settings. Its effectiveness has been proven for common clinical conditions in critical care such as cardiogenic pulmonary edema and chronic obstructive pulmonary disease exacerbations. Since the first pioneering studies of noninvasive ventilation in critical care in the late 1980s, thousands of studies and articles have been published on this topic. Interestingly, some aspects remain controversial (e.g. its use in de-novo hypoxemic respiratory failure, role of sedation, self-induced lung injury). Moreover, the role of NIV has recently been questioned and reconsidered in light of the recent reports of new techniques such as high-fl…

Research Reportmedicine.medical_specialtyExacerbationCritical CareCPAP; Non invasive ventilation; Respiratory failure; Critical Care; Critical Illness; Expert Testimony; Forecasting; Humans; Noninvasive Ventilation; Randomized Controlled Trials as Topic; Research Report; Surveys and Questionnaires; Anesthesiology and Pain MedicineCritical IllnessCPAP; Non invasive ventilation; Respiratory failure; Anesthesiology and Pain MedicinePatient characteristicsLung injuryRespiratory failure[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractlaw.inventionlcsh:RD78.3-87.303 medical and health sciences0302 clinical medicineRandomized controlled triallawCPAPAnesthesiologySurveys and QuestionnairesSettore MED/41 - ANESTESIOLOGIAmedicineHumans030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicineExpert TestimonyRandomized Controlled Trials as TopicNoninvasive VentilationCritically illbusiness.industryNon invasive ventilation3. Good healthAnesthesiology and Pain Medicine030228 respiratory systemRespiratory failurelcsh:AnesthesiologyCritical Illne[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractNoninvasive ventilationCPAP; Non invasive ventilation; Respiratory failurebusinessHumanResearch ArticleForecasting
researchProduct

The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes

2015

Background. Critically ill patients appear to be at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism during their stay in the intensive care unit (ICU). However, little is known about the clinical course of venous thromboembolism in the ICU setting. We therefore evaluated, through a systematic review of the literature, the available data on the impact of a diagnosis of DVT on hospital and ICU stay, duration of mechanical ventilation and mortality in critically ill patients. We also tried to determine whether currently adopted prophylactic measures need to be revised and improved in the ICU setting. Materials and methods. MEDLINE and EMBASE databases were searched up…

RiskCritical IllnessIntensive Care UnitCritically ill patients; Deep vein thrombosis; Meta-analysis; Outcomes; Cohort Studies; Hospital Mortality; Humans; Intensive Care Units; Length of Stay; Pulmonary Embolism; Randomized Controlled Trials as Topic; Research Design; Respiration Artificial; Risk; Thrombophilia; Treatment Outcome; Venous Thrombosis; Critical Illness; Hematology; Immunology and AllergyReviewDeep Vein Thrombosis Critically Ill Patients outcomes metanalysisCohort StudiesDeep vein thrombosiImmunology and AllergyHumansThrombophiliaMeta-analysiVenous ThrombosiHospital MortalityOutcomeRandomized Controlled Trials as TopicVenous ThrombosisHematologyLength of StayRespiration ArtificialIntensive Care UnitsTreatment OutcomeResearch DesignCritical IllneCritically ill patientCohort StudiePulmonary EmbolismHuman
researchProduct

[Choosing a quality-of-life questionnaire].

2006

International audience; Define the objective of the questionnaire: Discrimination: do you want a questionnaire to enable you to describe the quality of life of patients or to compare the quality of life between groups of patients, for example, to determine who has improved and who has gotten worse? Assessment: do you want a questionnaire to help you measure changes over time (improvement or aggravation) in your patients? Determine the properties of instruments necessary for this objective: If the objective is discrimination, analyze: construct validity, reliability. If the objective is assessment, analyze construct validity, sensitivity to changes. Choose the general category of questionnai…

Time FactorsHealth StatusMESH : Randomized Controlled Trials as TopicMESH : Multicenter Studies as Topic[ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesSurveys and QuestionnairesActivities of Daily LivingHumansMulticenter Studies as TopicMESH : Health StatusMESH: Health StatusRandomized Controlled Trials as TopicMESH: HumansMESH: QuestionnairesMESH: Activities of Daily LivingMESH: Time FactorsMESH : HumansMESH: Quality of Life[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH : QuestionnairesMESH : Follow-Up StudiesMESH: Follow-Up StudiesMESH : Quality of LifeMESH: Randomized Controlled Trials as TopicQuality of LifeMESH: Multicenter Studies as TopicMESH : Activities of Daily Living[SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesFollow-Up StudiesMESH : Time Factors
researchProduct